研判2025！中国经导管主动脉瓣置换术(TAVR)行业发展历程、市场现状、产品获批情况及发展趋势分析：技术发展迅速，行业规模稳健增长[图]

Core Insights - Transcatheter Aortic Valve Replacement (TAVR) has rapidly developed since its inception in 2002, becoming a crucial treatment for elderly patients with aortic stenosis (AS) and aortic regurgitation (AR) [1][7] - In 2024, TAVR procedures in China reached 17,232, marking a 24.2% increase from 2023, with a cumulative total of 55,083 procedures [1][7] - The TAVR market in China has grown from 40 million yuan in 2017 to over 1.8 billion yuan in 2024, achieving a compound annual growth rate of 71.7% [9][10] Industry Overview - TAVR is a minimally invasive procedure that involves delivering a compressed artificial aortic valve via catheter to replace a diseased valve [2] - The primary access route for TAVR is through the femoral artery (TF), accounting for 79.9% of procedures, followed by the apical approach at 18.4% [7][8] Surgical Outcomes - The success rate of TAVR devices has increased to 96.16% by 2024, with a declining trend in perioperative mortality rates [8] - The procedure's safety and effectiveness have improved, as evidenced by decreasing rates of postoperative complications [8] Regulatory Approvals - By September 2025, multiple TAVR systems have been approved in China, with companies such as Peijia Medical Technology and Shanghai MicroPort Medical Technology among the applicants [10][11] Future Trends - The TAVR patient demographic is becoming younger, with ongoing research focusing on lifecycle management strategies and new valve materials [11][12] - Advancements in artificial intelligence are expected to enhance preoperative imaging analysis, surgical decision-making, and postoperative risk assessment in TAVR procedures [12]